GOSS
HealthcareGossamer Bio, Inc.
$2.74
$-0.14 (-4.86%)
Jan 5, 2026
Price History (1Y)
Analysis
Gossamer Bio, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $634.19M and 144 employees. The company's revenue has grown by 40.2% year-over-year, reaching $44.05M in the trailing twelve months. The company's financial health reveals significant losses. Net income and EBITDA have been negative, at -$156,160,992 and -$153,215,008 respectively, resulting in operating and profit margins of -313.2% and 0.0%. Free cash flow is also negative, at -$82,003,128. However, the company maintains a significant cash position with $180.22M and has moderate debt obligations at $202.88M. Gossamer Bio's valuation metrics indicate a price to sales ratio of 14.40, while forward P/E is -4.67 and EV/EBITDA stands at -4.29. The company does not pay dividends, with a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $634.19M
- P/E Ratio
- N/A
- 52-Week High
- $3.87
- 52-Week Low
- $0.76
- Avg Volume
- 3.45M
- Beta
- 1.93
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 144